WHO ICTRP trial
Prospective, multicenter randomized controlled clinical study of radical…
ChiCTR2000034072 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000034072 |
|---|---|
| Public title | Prospective, multicenter randomized controlled clinical study of radical concurrent chemotherapy and radiotherapy combined with PD-1 antibody SHR-1210 in the treatment of stage III-IVA cervical cancer |
| Scientific title | Prospective, multicenter randomized controlled clinical study of radical concurrent chemotherapy and radiotherapy combined with PD-1 antibody SHR-1210 in the treatment of stage III-IVA cervical cancer |
| Primary sponsor | Southern Hospital of Southern Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Cervical cancer |
| Interventions | experimental group:Radiation therapy + 5 cycles of cisplatin concurrent chemotherapy + Carrizumab;control group:Cisplatin + concurrent radiotherapy |
| Registration date | Jun 22, 2020 |
| Target size | experimental group:86;control group:86 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: